Guardant Health, Inc.

ISIN US40131M1099

 | 

WKN A2N5RY

Market cap (in EUR)
12,059 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in December 2011 and is headquartered in Palo Alto, CA.
Show more Show less
Healthcare Healthcare Equipment United States

Financials

Key metrics

Market capitalisation, EUR 12,059 m
EPS, EUR -2.91
P/B ratio 57.4
P/E ratio -
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 683 m
Net income, EUR -403 m
Profit margin -59.05%

What ETF is Guardant Health, Inc. in?

There are 4 ETFs which contain Guardant Health, Inc.. All of these ETFs are listed in the table below. The ETF with the largest weighting of Guardant Health, Inc. is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 1.07%
Equity
United States
Health Care
Biotech
45
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.01%
Equity
World
Social/Environmental
497
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing 0.02%
Equity
North America
Social/Environmental
27
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.21%
Equity
United States
Small Cap
185
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.